Astellas Lifts View as Cancer Drugs Drive Profit to 2016 High
The Astellas Pharma headquarters in Tokyo, Japan.
Photographer: Akio Kon/BloombergAstellas Pharma Inc. raised its outlook after strong sales of its cancer drugs drove quarterly earnings to their highest since at least 2016.
The Japanese drugmaker raised its full-year operating profit goal by 50% to ¥240 billion ($1.6 billion), attributing the lift to the strong demand for its bladder cancer therapy Padcev and stomach cancer drug Vyloy.